Queensland Clinical Trials and Biostatistics Centre

QCTBC promotes and runs high quality clinical trials and other non-trial clinical studies.

University of Queensland

The Queensland Clinical Trials & Biostatistics Centre (QCTBC) was formed in September 2009 and is a school centre within The University of Queensland's School of Population Health. The Centre aims to promote and run high quality clinical, non-clinical and biostatistical methodological studies, both locally and internationally.

QCTBC provides expertise and infrastructure to design, conduct, and facilitate high quality clinical trials, non-trial clinical studies and biostatistical research with both academic and industry collaborators. All professionals within the Centre are GCP trained, and conduct clinical studies strictly according to the regulatory requirements and pharmaceutical industry standard. The Centre is currently involved in Phase 1, -2 and -3 clinical trials in various therapeutic areas, and is at the head of several clinical studies including the evaluation of cardiometabolic effects of new anti-diabetes drug (GLP-1R agonists), identification and validation of 'omics' based biomarkers to understand the progression to auto-immune and metabolic diseases, and clinical epidemiological studies in diabetes and cardiovascular diseases using large longitudinal data. QCTBC also provides high quality consulting services to clinical researchers and bio-pharmaceutical companies.

The Centre plays a central role in the development of Australia’s translational research capabilities, and is one of the principal members of the TIA Queensland Node, Therapeutic Innovation Australia. The purpose of the TIA-QLD Node is to provide a facilitated pathway to assist Australian life sciences discovery researchers to progress their inventions through the various nonclinical and clinical development steps to the point where they will attract investment for commercialisation into products for improving human health. The Centre has achieved international prominence through numerous collaborations with international institutes and multinational pharmaceutical companies.